focus -WSS

focus

author：focus 2025-10-01 15:00:10 - browse：68826

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： WHO recommends dropping component of many flu vaccines

leisure time

hotspot

WSS

Covid vaccines: Private market messier than government rollout

Using force crossed my mind when examining a defiant young patient

CDC panel: People 65 and older should get a Covid spring booster shot

Cholera vaccine supplies dangerously low, outbreaks surging

STAT Madness 2024: Meet the contenders

Sudafed saga points to U.S. issues with evaluating older drugs

focus

focus

explore

Medical records are filled with copy

Change Healthcare cyberattack shows risk of industry consolidation

Hepatitis C has a cure — but many Americans still lack access to it

Laying a path for careers in science

The high cost of giving birth even with insurance

Did you have Obamacare on your GOP debate bingo card?

Activists slam private health insurers over coverage restrictions

Ohio train derailment: Experts on toxic chemical risks

Psychedelics group wrestles with new pharma identity

CDC advisory group OKs chikungunya vaccine

entertainment

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Data show record exodus of life scientists from academia

Did you have Obamacare on your GOP debate bingo card?

Laying a path for careers in science

CDC panel: People 65 and older should get a Covid spring booster shot

leisure time

hotspot

knowledge

hotspot